Supriya Gupta

US Patent:

8298530, Oct 30, 2012

Filed:

Aug 12, 2009

Appl. No.:

12/540320

Inventors:

Elizabet A. Kaisheva - Belmont CA, US
Aleni Flores-Nate - Union City CA, US
Supriya Gupta - Sunnyvale CA, US

Assignee:

Facet Biotech Corporation - Redwood City CA

International Classification:

A61K 39/395

US Classification:

4241301, 4241411, 4241441

Abstract:

This invention is directed to a stable lyophilized pharmaceutical formulation prepared by lyophilizing an aqueous formulation comprising a high concentration, e. g. 50 mg/ml or more, of an IgG antibody in about 5-25 mM histidine buffer having pH from about 5. 5 to about 6. 5, about 0. 005%-0. 03% polysorbate, sucrose, and optionally serine, and/or mannitol. This lyophilized formulation is stable at room temperature for at least 6 months, and preferably 1 year. This lyophilized formulation has a short reconstitution time of less than 2 minutes, and is suitable for parenteral administration such as intravenous, intramuscular, intraperitoneal, or subcutaneous injection. This invention is exemplified by the anti-IL2 receptor antibody.

US Patent:

8465739, Jun 18, 2013

Filed:

Sep 6, 2011

Appl. No.:

13/226372

Inventors:

Elizabet A. Kaisheva - Belmont CA, US
Supriya Gupta - Sunnyvale CA, US
Shanti G. Duvur - Fremont CA, US
Malathy Subramanian - Fremont CA, US

Assignee:

Abbvie Biotherapeutics Inc. - Redwood City CA

International Classification:

A61K 39/395

US Classification:

4241301, 4241411, 4241441

Abstract:

This invention is directed to a stable liquid pharmaceutical formulation comprising a high concentration, e. g. 50 mg/ml or more, of antibody in about 20-60 mM succinate buffer or 30-70 mM histidine buffer, having pH from about pH 5. 5 to about pH 6. 5, about 0. 01-0. 1% polysorbate, and a tonicity modifier that contributes to the isotonicity of the formulation. This liquid formulation is stable at refrigerated temperature (2-8 C. ) for at least 1 year, and preferably 2 years. This liquid formulation is suitable for subcutaneous injection. The preferred antibodies include Daclizumab, a humanized anti-IL-2 receptor monoclonal antibody; HAIL-12, a humanized anti-IL-12 monoclonal antibody; HuEP5C7, a humanized anti-L selectin monoclonal antibody; and Flintozumab, a humanized anti-gamma interferon monoclonal antibody.

US Patent:

20030113316, Jun 19, 2003

Filed:

Jul 25, 2002

Appl. No.:

10/206469

Inventors:

Elizabet Kaisheva - Belmont CA, US
Aleni Flores-Nate - Union City CA, US
Supriya Gupta - Sunnyvale CA, US

International Classification:

A61K039/395

US Classification:

424/130100

Abstract:

This invention is directed to a stable lyophilized pharmaceutical formulation prepared by lyophilizing an aqueous formulation comprising a high concentration, e.g. 50 mg/ml or more, of an IgG antibody in about 5-25 mM histidine buffer having pH from about 5.5 to about 6.5, about 0.005%-0.03% polysorbate, sucrose, and optionally serine, and/or mannitol. This lyophilized formulation is stable at room temperature for at least 6 months, and preferably 1 year. This lyophilized formulation has a short reconstitution time of less than 2 minutes, and is suitable for parenteral administration such as intravenous, intramuscular, intraperitoneal, or subcutaneous injection. This invention is exemplified by the anti-IL2 receptor antibody.

US Patent:

20030138417, Jul 24, 2003

Filed:

Nov 8, 2002

Appl. No.:

10/291528

Inventors:

Elizabet Kaisheva - Belmont CA, US
Supriya Gupta - Sunnyvale CA, US
Shanti Duvur - Fremont CA, US
Malathy Subramanian - Fremont CA, US

International Classification:

A61K039/395

US Classification:

424/130100

Abstract:

This invention is directed to a stable liquid pharmaceutical formulation comprising a high concentration, e.g. 50 mg/ml or more, of antibody in about 20-60 mM succinate buffer or 30-70 mM histidine buffer, having pH from about pH 5.5 to about pH 6.5, about 0.01-0.1% polysorbate, and a tonicity modifier that contributes to the isotonicity of the formulation. This liquid formulation is stable at refrigerated temperature (2-8 C.) for at least 1 year, and preferably 2 years. This liquid formulation is suitable for subcutaneous injection. The preferred antibodies include Daclizumab, a humanized anti-IL-2 receptor monoclonal antibody; HAIL-12, a humanized anti-IL-12 monoclonal antibody; HuEP5C7, a humanized anti-L selectin monoclonal antibody; and Flintozumab, a humanized anti-gamma interferon monoclonal antibody.

US Patent:

20040009168, Jan 15, 2004

Filed:

Apr 7, 2003

Appl. No.:

10/409477

Inventors:

Elizabet Kaisheva - Belmont CA, US
Supriya Gupta - Sunnyvale CA, US

International Classification:

A61K039/395

US Classification:

424/141100, 424/144100

Abstract:

This invention is directed to a multidose pharmaceutical formulation comprising an antibody with one or more preservatives. This formulation is effective in inhibiting the growth of microorganisms. This formulation further retains the physical, chemical, and biological stability of the antibody molecule. In one embodiment of the invention, the pharmaceutical formulation comprises an IgG antibody, 0.15-0.2% (w/v) chlorobutanol, and 0.3-0.5% (w/v) benzyl alcohol. In another embodiment of the invention, the pharmaceutical formulation comprises an IgG antibody, 0.1-0.2% (w/v) chlorobutanol, and 0.05-0.1% (w/v) methyl paraben. In yet another embodiment of the invention, the pharmaceutical formulation comprises an IgG antibody and 0.5-0.75% benzyl alcohol.

US Patent:

20060008415, Jan 12, 2006

Filed:

Jun 24, 2005

Appl. No.:

11/166906

Inventors:

Elisabet Kaisheva - Belmont CA, US
Supriya Gupta - Sunnyvale CA, US
Weichang Zhou - Livermore CA, US
Robert Weinkam - San Carlos CA, US
Patrick Powers - Palo Alto CA, US
Naichi Liu - San Jose CA, US
Vanitha Ramakrishnan - Belmont CA, US

Assignee:

Protein Design Labs, Inc. - Fremont CA

International Classification:

A61K 51/00
A61K 39/395

US Classification:

424001490, 424130100

Abstract:

The present invention is directed to stable protein derivatives, e.g., antibodies, antibody fragments or peptides, with at least one free thiol group coupled to N-acetyl-L-cysteine, N-ethyl-maleimide, or cysteine and the methods of making such derivatives. In addition, stable liquid pharmaceutical formulations comprising such proteins or their derivatives and stable lyophilized pharmaceutical formulations comprising such proteins are provided. The present invention is also directed to a method of making a stable Fab′ fragment of an antibody and a method of controlling vascularization in injured or cancerous tissue comprising applying to the injured tissue one or more doses of the pharmaceutical formulations.

US Patent:

20060029599, Feb 9, 2006

Filed:

Oct 14, 2005

Appl. No.:

11/250835

Inventors:

Elizabet Kaisheva - Belmont CA, US
Aleni Flores-Nate - Union City CA, US
Supriya Gupta - Sunnyvale CA, US

International Classification:

A61K 39/395

US Classification:

424133100

Abstract:

This invention is directed to a stable lyophilized pharmaceutical formulation prepared by lyophilizing an aqueous formulation comprising a high concentration, e.g. 50 mg/ml or more, of an IgG antibody in about 5-25 mM histidine buffer having pH from about 5.5 to about 6.5, about 0.005%-0.03% polysorbate, sucrose, and optionally serine, and/or mannitol. This lyophilized formulation is stable at room temperature for at least 6 months, and preferably 1 year. This lyophilized formulation has a short reconstitution time of less than 2 minutes, and is suitable for parenteral administration such as intravenous, intramuscular, intraperitoneal, or subcutaneous injection. This invention is exemplified by the anti-IL2 receptor antibody.

US Patent:

20070244166, Oct 18, 2007

Filed:

Apr 18, 2007

Appl. No.:

11/737067

Inventors:

Supriya Gupta - Sunnyvale CA, US
Yanli Mi - La Jolla CA, US
Camellia Zamiri - Fremont CA, US

Assignee:

PDL BioPharma, Inc. - Fremont CA

International Classification:

A61K 31/455

US Classification:

514355000

Abstract:

Provided herein are ready-to-use premixed bolus injection pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.